Pulmotil G100 Premix for Medicated Feedingstuff

Country: Միացյալ Թագավորություն

language: անգլերեն

source: VMD (Veterinary Medicines Directorate)

buyitnow

SPC SPC (SPC)
14-04-2020

active_ingredient:

Tilmicosin

MAH:

Eli Lilly and Company Limited

ATC_code:

QJ01FA91

INN:

Tilmicosin

pharmaceutical_form:

Premix for medicated feeding stuff

prescription_type:

POM-V - Prescription Only Medicine – Veterinarian

therapeutic_group:

Pigs, Rabbits

therapeutic_area:

Antimicrobial

authorization_status:

Authorized

authorization_date:

1995-11-17

SPC

                                AN: 00506/2013
Revised: October 2013
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Pulmotil G100 Premix for Medicated Feedingstuff
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Tilmicosin (as phosphate)
100 g/kg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Premix for medicated feeding stuff.
A yellowish tan to reddish tan free-flowing granular material.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs and rabbits.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Pigs: Prevention and treatment of respiratory disease caused by
_Actinobacillus _
_pleuropneumoniae,_
_ _
_Mycoplasma _
_hyopneumoniae,_
_Pasteurella multocida_ and other organisms sensitive to tilmicosin.
Rabbits: Prevention and treatment of respiratory disease caused by
_Pasteurella multocida_ and
_Bordetella bronchiseptica_, susceptible to tilmicosin.
4.3
CONTRAINDICATIONS
Horses or other Equidae, must not be allowed access to feeds
containing tilmicosin. Horses fed with tilmicosin medicated feeds may
present signs of toxicity with lethargy, anorexia, reduction of feed
consumption, loose stools, colic, distension of the abdomen and death.
Do not use in case of hypersensitivity to tilmicosin or to any of the
excipients
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Under practical conditions, the management of respiratory disease
outbreaks recognises that acutely ill animals are inappetant and
require
parenteral therapy.
Page 1 of 7
AN: 00506/2013
Revised: October 2013
4.5
SPECIAL PRECAUTIONS FOR USE
i)
Special precautions for use in animals
Inappropriate use of the product may increase the prevalence of
bacteria resistant to tilmicosin and may decrease the effectiveness of
treatment with tilmicosin related substances.
Official, national and regional antimicrobial policies should be taken
into
account when the product is used.
Due to the likely variability (time, geographical) in the occurrence
of the
resistance of bacteria for
tilmicosin, bacteriological
sampling and suscepti
                                
                                read_full_document